Delhi: Half of vaccination centres for 18+ closed, says Atishi

Less than a day's stock of Covid-19 vaccine is left for people in the 18-44 age group: Atishi

Atishi Marlena
Atishi Marlena | File photo
Press Trust of India New Delhi
2 min read Last Updated : Jun 15 2021 | 8:12 PM IST

Less than a day's stock of COVID-19 vaccine is left for people in the 18-44 age group, due to which half of the vaccination centres for such beneficiaries closed down on Tuesday and the remaining half will shut the next day if the stock is not replenished, AAP MLA Atishi said.

In a vaccination bulletin issued online on Tuesday, she also said the position is "quite comfortable" for people aged 45 and above, and over 50 per cent of eligible people in this group have been vaccinated.

"As the unlock is slowing happening and offices and markets are reopening, the youth segment will venture out more, and therefore, it was important that they would get vaccinated. Our drive for the 18+ years category was again picking pace, but for lack of doses, it has slowed down again," she said.

Atishi said less than a day's stock of COVID-19 vaccine is left for people in the age group of 18-44, due to which "half of the vaccination centres for such beneficiaries closed down today and the remaining half will shut tomorrow" if the stock is not replenished.

She appealed to the Centre to send more vaccine doses urgently to carry forward the vaccination process for the 18-44 age group segment.

According to vaccine stock for people aged 45 and above, as on June 15 morning, she said 7,95,000 doses were available, out of which Covaxin doses will last for 22 days and Covishield doses for 43 days.

On June 14, a total of 60,734 vaccine doses were administered, taking the total number of doses given till date to 61,50,931, according to the bulletin.

For healthcare workers, frontline workers and 45 and above age group, 784 centres are running at 626 locations, while for the 18-44 group, 64 centres across 36 locations were earmarked, the bulletin said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 15 2021 | 8:01 PM IST

Next Story